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Abstract
Introduction The importance of elucidating the relationships between pain, mood and quality of life (QoL) amongst people 
with amyotrophic lateral sclerosis/motor neuron disease is evident to clinicians, yet the literature is limited and inconsistent. 
We explored the relationships between pain, depression, anxiety and QoL to reconcile the previous contrasting findings and 
inform future research and clinical practice.
Methods Patient-reported outcomes were obtained as part of the Trajectories of Outcomes in Neurological Conditions study. 
Mood and QoL scales underwent Rasch analysis. Correlation coefficients examined the strength of association between 
variables of interest. A bivariate regression model was developed to examine the effects of pain, depression and anxiety on 
joint psychological and physical QoL domains.
Results Of 636 people with ALS, 69% reported pain, of these most had mild pain. Seven percent (7%) of participants 
exceeded published cutoffs for probable depression and 14% had probable anxiety. Pain, depression and anxiety all influence 
quality of life; depression has a significant effect on both physical and psychological domains of QoL, whereas pain affects 
physical QoL and anxiety psychological QoL.
Conclusions These results show the importance of expressing quality of life in a conceptually appropriate way, as failing to 
take account of the multidimensional nature of QoL can result in important nuances being overlooked. Clinicians must be 
aware that pain, depression and anxiety all worsen QoL across their ranges, and not just when pain is severe or when anxiety 
or depression reach case level.
Keywords Amyotrophic lateral sclerosis (ALS) · Motor neuron disease (MND) · Quality of life · TONiC study · Anxiety · 
Depression · Pain
Introduction
Amyotrophic lateral sclerosis (ALS), also known as motor 
neuron disease (MND), is a progressive, neurodegenerative 
disease leading to paresis, dysarthria, dysphagia, respiratory 
failure and death. No curative treatment is currently avail-
able, so the paramount clinical consideration is symptom 
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relief to improve quality of life (QoL) [1]. Since QoL for 
people with ALS/MND is shaped not only by the physi-
cal manifestations of the disease, but also by the psycho-
social effects of living with a terminal, disabling illness, 
these symptoms range from physical aspects such as pain 
to psychological aspects such as depression and anxiety [2].
A recent review highlighted pain as a symptom which 
is poorly understood amongst ALS/MND populations [3]. 
The hypothesis that pain would reduce QoL was supported 
by one study of 40 patients with ALS/MND [4] but refuted 
by another study analysing 36 patients, which found that the 
effect of pain intensity upon QoL was no longer significant 
once depression scores were added as a possible confound-
ing covariate [5].
Psychological distress, including depression and anxiety, 
might be predicted to worsen QoL among those with ALS/
MND but again the literature is conflicting. While there are 
a number of studies reporting that depression does adversely 
affect QoL [5–12], there are many finding no correlation [2, 
13–15] or variable findings [16–18]. Similarly, the literature 
on anxiety ranges from those linking anxiety with a worse 
QoL [19–21] to several reporting no correlation [2, 14, 15]. 
These contrasting findings have not yet been explained; 
speculation that small sample sizes may have led to unrepre-
sentative cohorts is refuted by variation regarding the effect 
of depression on QoL among studies of at least 100 patients, 
where again there are conflicting results finding negative [7, 
10, 11] or no correlation [13]. Consideration that choice of 
outcome measure for depression or anxiety may be respon-
sible for these contrasting results is contradicted by different 
conclusions even when the same measure is used. Studies 
on the relation between anxiety and depression with QoL 
in ALS/MND using the Hospital Anxiety and Depression 
scale (HADS) have shown an association between anxiety 
and QoL [21], or depression and QoL [10], or conversely no 
relation for either anxiety or depression [2, 14].
The ongoing Trajectories of Outcomes in Neurologi-
cal Conditions (TONiC) study in people with ALS/MND 
examines the relationships between QoL and a number of 
potential factors which could be influenced by clinical care. 
TONiC-ALS involves a number of phases and began with 
qualitative work with people with ALS/MND, through 1:1 
interviews and focus groups, to identify which factors people 
living with the condition believed influential on their QoL. 
To ascertain which factors are believed amenable to clinical 
care and to increase the likelihood that findings would trans-
late to practice, we followed the patient-centred, qualitative 
work with a nationally promoted, online forum for health 
and social care professionals to ascertain the face valid-
ity of the patient findings among professionals [22]. These 
processes showed that despite the variation in the literature 
findings, patients and professionals alike believe that pain, 
anxiety and depression all influence QoL for people with 
ALS/MND. People with ALS/MND described their QoL 
as involving physical, psychological and other aspects, in 
keeping with the World Health Organization’s recognition 
of the multidimensional nature of QoL [23].
The aim of this paper is to examine the prevalence of 
pain, anxiety, and depression in a large sample of people 
with ALS/MND, and examine their inter-relationships and 
effect on QoL, utilising a measure that recognises the multi-
faceted nature of QoL. We also sought to reconcile the previ-
ous contrasting findings to inform future research.
Methods
Data collection
Participants with ALS/MND, diagnosed according to El 
Escorial World Federation of Neurology criteria for the 
diagnosis of ALS [24], were recruited into the ongoing 
TONiC study from specialist clinics across the United King-
dom using a convenience sampling strategy. Cases with a 
family history of ALS/MND were eligible as were patients 
with only lower motor neuron (LMN) signs in two or more 
regions, or with progressive primary lateral sclerosis without 
spinal LMN signs, provided a consultant neurologist special-
ising in ALS/MND had confirmed the diagnosis. Eligibility 
criteria were wide and inclusive, permitting participants to 
join irrespective of level of disability, duration of disease or 
subtype of MND (amyotrophic lateral sclerosis, progressive 
bulbar palsy, progressive muscular atrophy, primary lateral 
sclerosis). Participants were excluded if they were unable 
to give informed consent or unable to complete self-report 
questionnaires even with help from a scribe. Participants 
were not eligible if they had cognitive impairment preclud-
ing them being able to select responses on patient-reported 
outcomes (PROs) or if they had significant concomitant 
conditions which would have influenced their answers to 
the PROs. Inclusion and exclusion criteria were assessed 
by a specialist healthcare worker prior to enrollment in the 
study. Not all approached patients agreed to participate, 
typically because of perceived lack of time or because they 
preferred not to think about MND and its effects. Following 
informed consent, participants completed a questionnaire 
pack containing demographic and disease-specific data such 
as duration from diagnosis (all UK MND clinics follow rapid 
diagnosis pathways), as well as a range of patient-reported 
measures [25].
The measures included:
1. World Health Organization Quality of Life questionnaire 
(WHOQOL-BREF) [26]—the scale measures generic 
quality of life across four domains: physical health 
(seven items, with operational score range of 0–28), 
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psychological health (six items, with operational score 
range 0–24), environment and social relationships [23]. 
The physical health domain was designed to incorporate 
pain, amongst other factors, whereas it was intended that 
the psychological health domain would incorporate posi-
tive and negative feelings, amongst other factors.
2. Hospital Anxiety and Depression Scale for MND 
(mHADS) [27]—a version of the HADS has been pre-
viously validated by Rasch analysis for use in an MND 
population, with removal of two items from the original 
14-item scale. The modified summed raw-score cut-
points of between five and seven indicate a possible 
case, and above or equal to eight indicate a probable 
case of depression. Similarly, scores between seven and 
eight indicate a possible case, and above or equal to nine 
indicate a probable case for the anxiety scale.
3. Pain—this was measured by a numeric rating scale 
(NRS), anchored as 0—no pain and 10—severe pain, 
to describe overall pain level. Pain was treated as a con-
tinuous variable in the analysis.
Rasch analysis
Interval level estimates for each person were calculated for 
the anxiety and depression scales of the mHADS and the 
WHOQOL-BREF physical and psychological domains, by 
Rasch analysis (see supplementary) [28, 29]. The explained 
common variance (ECV) is reported where a value of 1 
indicates that all non-error variance is contained within 
the latent estimate. An ECV value > 0.9 is considered suf-
ficient to indicate that the first common factor is essentially 
unidimensional [30]. Full details of this process are given 
elsewhere [31–33]. The resulting interval level transforma-
tions were translated to the original operational range of 
each scale.
Other statistical analyses
Summary statistics were produced as part of the initial data 
investigation. Pearson’s (or where appropriate Kendall’s) 
correlation coefficients were calculated to examine the 
strength of association between variables of interest. A type 
2 MANOVA was used to test the null hypothesis that there 
is no effect of pain, anxiety, and depression on the joint dis-
tribution of physical and psychological QoL. Following this 
investigation, a statistical modelling analysis was performed 
to assess the joint effects of pain, depression and anxiety on 
the psychological and physical QoL domains.
Our model is an extension of the standard linear regres-
sion model by accommodating two dependent variables, 
which are assumed to follow a bivariate normal distribu-
tion. The dependent variables are physical and psycho-
logical domains of QoL and the independent variables 
are pain, depression and anxiety. Bivariate models of this 
kind are able to take account of correlations amongst the 
dependent variables and so can be more powerful than 
separate multiple linear regressions for each variable [34]. 
A final model was selected following a process of forwards 
selection using the Pillai’s trace statistic [35], and interac-
tion effects between significant variables were tested for 
inclusion.
The results are shown in a coefficient plot, which illus-
trates the effects of each independent variable on the 
dependent variables by showing the parameter estimates 
and confidence ellipses for each coefficient in the model. 
The variables are standardised so that their corresponding 
regression parameter estimates can be compared directly. 
A joint, multivariate test of  H0: β = zero is rejected when 
the confidence ellipse does not cover the origin (labelled 
as  H0 on the plot). The size of each ellipse corresponds to 
the confidence in the parameter estimate whereby in 95% 
analyses, the ellipse will contain the true (but unknown) 
value of the parameter estimate.
Results
Participants
636 participants completed the questionnaire pack at time 
of analysis (Table 1).
Rasch analysis
Data from the physical and psychological domains of the 
WHOQOL-BREF and the anxiety and depression scales 
all fitted the Rasch model well, with non-significant total 
Chi square values. Reliability indicators were > 0.70, the 
conventional threshold for acceptability for group use. All 
ECV values were ≥ 0.9. Detailed summary fit statistics can 
be found in the supplementary material (Table S1).
Table 1  Descriptive statistics for the cohort
N 636
Age/years [mean (SD)] 65.12 (10.74)






Sex = M (%) 390 (61.3)
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Pain
The pain NRS was completed by 625/636 (98.3%) individu-
als, of whom 429 (68.6%) reported pain by giving a score 
above the zero anchor of no pain (Fig. 1). Median score was 
2 (IQR 2–4).
Mood
Mean depression measurement was 5.50 (SD 3.45) and mean 
anxiety measurement was 5.49 (SD 3.17). The proportions 
of participants with scores above the cut-points that indicate 
a possible or probable clinical case were: 29.1% for depres-
sion and 27.4% for anxiety. The proportions categorised as 
probable cases were much lower (Table 2).
Correlations between pain, mood and quality of life
597 individuals provided complete information about their 
pain, mood (mHADS anxiety and depression) and QoL. 
There were some strong correlations between these vari-
ables, for example, physical QoL was associated with psy-
chological QoL (Table 3). Pain was most strongly correlated 
with physical QoL, whereas depression and anxiety were 
most strongly correlated with psychological QoL.
Statistical model of physical and psychological 
quality of life domains
Acknowledging the strong correlation between physical 
and psychological QoL, we explored the influence of pain, 
depression and anxiety on their joint distribution. A type 2 
MANOVA was used to test the null hypothesis that there is 
no effect of pain, anxiety, and depression on the joint dis-
tribution of physical and psychological QoL. Interactions 
between the main effects were tested for, and an interaction 
effect between pain and depression was found to be signifi-
cant. The null hypothesis was rejected for each explanatory 
variable (Table 4). Depression explains more of the variance 
in the response variables than the other explanatory vari-
ables (Pillai test statistic = 0.33).
Model selection
A final model including pain, depression, anxiety and an 
interaction between pain and depression was identified. Each 
parameter is significant in the bivariate model for physical 
and psychological QoL (Table 5). Increased pain, depres-
sion, and anxiety are associated with a reduction in QoL. 
The positive coefficient for the interaction term between pain 
and depression suggests that there is a less than additive 
effect on QoL for those with both variables. Depression is 
the most influential factor for both QoL domains.
Coefficient plot
The coefficient plot provides a graphical interpretation of 
the results from the bivariate regression analysis (Fig. 2). 
It shows that all three factors of pain, depression and anxi-
ety influence the bivariate model of physical and psycho-
logical QoL, as the confidence ellipse for each one does 
not cross the origin  (H0). Note that the confidence ellipses 
for pain, and for the interaction term between pain and 
Fig. 1  A bar chart showing the responses to the pain numerical rating 
scale




Possible cases Probable 
cases
Total
Anxiety (%) 458 (72.6%) 85 (13.5%) 88 (13.9%) 631
Depression 
(%)
446 (70.9%) 137 (21.8%) 46 (7.3%) 629
Table 3  Correlation matrix of the main variables of interest
Kendall’s tau correlation coefficients are provided for the variables 
that are associated with pain, and Pearson’s correlation coefficients 
are given for the remaining associations
Pain Depression Anxiety Physical QoL
Depression 0.212
Anxiety 0.173 0.581
Physical QoL − 0.373 − 0.528 − 0.364
Psychological QoL − 0.191 − 0.726 − 0.615 0.601
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depression, include the zero value for psychological QoL, 
and that the confidence ellipse of anxiety includes the zero 
value for physical QoL.
Discussion
Pain is common in a large, national sample of people liv-
ing with ALS/MND, reported by 429/625 (68.6%). Across 
a numerical rating scale anchored between no pain (0) and 
severe pain (10), about half reported values of 1–4, and 
less than 5% reported values of 8–10. Like pain, mood is 
a continuum, which can be divided into probable, possi-
ble or unlikely cases according to the number and severity 
of depression or anxiety symptoms endorsed in the HADS 
[27]. Depression and anxiety were common; 7% had prob-
able depression, and 14% had probable anxiety, according to 
their mHADS. There were more participants who had pos-
sible depression (21.8%) and a smaller number with possible 
anxiety (13.5%). Many participants were unlikely to have 
anxiety (72.6%) or depression (70.9%). Using a bivariate 
statistical model, we were able to better elucidate the joint 
effects of pain and mood on the different domains of QoL. 
We described QoL in a conceptually appropriate way, using 
the joint distribution of psychological and physical QoL. 
The bivariate model shows that pain, depression, and anxiety 
affect physical and psychological QoL.
Previous smaller studies have found comparable preva-
lence of pain in ALS: 53.8% in a multicentre study (n = 80) 
[36], 56.9% in a regional study (n = 160) [37], and 78–85% 
in two small clinic-based studies (n = 46 or n = 42) [38, 39]. 
Those studies including a control group showed that pain 
in ALS/MND exceeded the population-based control rate 
[37–39]. The distribution of pain severity in our study is 
similar to an ALS patient online survey of 2664 respondents 
which found 39% report ‘none’, 34% report ‘mild’, and 6% 
report ‘severe’ [40]. A 2013 literature review of published 
research stated that the prevalence of pain in older people 
living in the community ranged from 20 to 46% [41]. Boer 
et al. used the NRS to assess pain amongst the general popu-
lation (n = 376; 89 (65.0%) men, mean age 53.2 years). Of 
the respondents, 36.4% (n = 137) reported pain complaints, 
with a mean NRS pain score of 4.65 (standard deviation 
(SD) = 2.05, range 1–9) [42]. Our large study showed that 
the prevalence of pain in those with ALS/MND is higher 
than the figures given above for the general population, 
although the pain intensity for those with pain is similarly 
mild.
Table 4  Results of the 
MANOVA of pain, anxiety 
and depression on physical and 
psychological QoL
a df1 and df2 are the degrees of freedom used in determining the F value i.e. F(df1, df2)
Variable Degrees of 
freedom




df1a df2a p value
Pain 1 0.184 69.143 2 612 < 0.0001
Depression 1 0.328 149.165 2 612 < 0.0001
Anxiety 1 0.122 42.623 2 612 < 0.0001
Pain × depression 1 0.024 7.497 2 612 < 0.001
Table 5  Standardised model parameters for the bivariate regression 




Std. error t value Pr(> |t|)
Physical QoL
 Intercept 14.467 0.121 119.868 < 2e−16
 Pain − 1.434 0.123 − 11.679 < 2e−16
 Depression − 1.493 0.146 − 10.241 < 2e−16
 Anxiety − 0.210 0.144 − 1.457 0.146
 Pain × depression 0.442 0.116 3.821 < 0.001
Psychological QoL
 Intercept 13.596 0.088 154.235 < 2e−16
 Pain − 0.112 0.090 − 1.246 0.213
 Depression − 1.783 0.106 − 16.753 < 2e−16
 Anxiety − 0.946 0.105 − 8.986 < 2e−16
 Pain × depression 0.074 0.085 0.870 0.385
Fig. 2  Coefficient plot for the parameters of the bivariate model
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This study highlights the importance of quantifying QoL 
in an appropriate way. Considering both physical and psy-
chological aspects of QoL in ALS/MND jointly facilitated 
a greater understanding of how pain, depression and anxiety 
affect QoL. Pain, depression and anxiety influence differ-
ent domains of QoL, as was proposed a priori when the 
WHOQOL-BREF was developed [23]. The model shows 
that pain influences physical QoL more than psychological 
QoL, whereas depression has a large influence on both phys-
ical and psychological QoL. Anxiety is highly correlated 
with psychological QoL and mildly correlated with physi-
cal QoL. Earlier work suggested that pain was significantly 
correlated to overall QoL, physical wellbeing and existential 
wellbeing, but not psychological wellbeing [4]. A literature 
search on the relationships between pain, mood and QoL in 
ALS shows just one other paper reporting a linear regression 
model investigating pain, depression and QoL in a sample of 
36 ALS patients [5]. They found a weak association between 
increasing pain and lower QoL, which was no longer signifi-
cant once depression was accounted for. The QoL measure 
used was the Spitzer QoL index [43], which is reported as a 
single number between 0 and 10. Using a multidimensional 
description of QoL in our model allows a fuller depiction of 
QoL compared to a single-item measure [18].
Many of the earlier studies which also found negative 
correlations between QoL and depression [6–8, 10], or anxi-
ety [19–21] used multidimensional QoL measures. Those 
studies not finding correlations between QoL with depres-
sion or anxiety used single-item measures of QoL [13], or 
subject-specific measures, where respondents nominate and 
indicate the relative importance of QoL domains [2, 14, 16]. 
Using regression analyses, Sandstedt et al. found that depres-
sion and anxiety, as assessed by the HADS, were associated 
with the psychosocial score rather than physical score in the 
Sickness Impact Profile measure for QoL [18].
It has been suggested that anxiety often co-exists with 
depression in ALS [44], which may lead to over-reporting of 
the contribution of anxiety to QoL in analyses where depres-
sion has not been accounted for. This incongruity stresses 
the importance of interpreting statistical analyses with care. 
For example, using the TONiC dataset, we performed a sim-
ple multiple regression of the effects of anxiety, depression 
and pain on overall QoL (see supplementary); anxiety was 
not significant in the multiple regression model for over-
all QoL once pain and depression had been accounted for. 
In view of our large sample size, this result is likely to be 
due to the high correlations amongst pain, depression and 
anxiety. In the bivariate model for physical and psychologi-
cal QoL, anxiety remained a significant contributor even 
after pain and depression were accounted for. These find-
ings are in keeping with a review concluding that higher 
levels of anxiety and depression were associated with poorer 
QoL in ALS/MND [1]. Our final model included a positive 
interaction term between pain and depression; for those 
with both depression and pain, the effect on QoL is slightly 
less than the additive effect that might otherwise have been 
inferred from a model that does not account for co-existent 
symptoms.
The strengths of this work include the large sample size 
(N = 625) collected nationally, that pain and mood informa-
tion were collected as part of a wider assessment so that the 
data reflect general patient experience, and the use of a QoL 
measure which reflected the viewpoint of people with ALS/
MND that their QoL was influenced by physical, psychologi-
cal and other components. The limitations of this work are 
its cross-sectional design so causality cannot be determined. 
A longitudinal extension providing repeated measurements 
over time is under way to allow these aspects to be inves-
tigated. Patients with cognitive impairment were ineligible 
to participate in this study and the findings of this study 
will not necessarily be relevant for ALS/MND patients with 
cognitive impairment. Minor cognitive impairment amongst 
participants was not assessed, and further work could aim to 
explore any effect of cognitive impairment on the relation-
ship between pain, depression and anxiety on QoL.
This study highlights the adverse effects of pain, depres-
sion, and anxiety on QoL for those living with ALS/MND. 
Clinicians should routinely enquire about pain as they do 
for other symptoms such as orthopnea or emotional lability. 
Pain offers a potentially important treatment target since this 
symptom influences quality of life, has many treatments, 
and is common, with almost 70% of people with ALS/MND 
experiencing some level of pain. The Practice Parameters of 
the American Academy of Neurology [45] and the European 
Guidelines on the Clinical Management of ALS [46] discuss 
the treatment of pain for patients with ALS/MND and the 
topic has been extensively reviewed [3].
There is consensus among experts that patients with 
ALS/MND who are diagnosed with either depression or 
anxiety may require treatment but both the American and 
European guidelines note the absence of systematic trials 
[45, 46]. Guidelines comment that the choice of antidepres-
sant may be influenced by additional symptoms (e.g. sialor-
rhoea, insomnia, apathy, appetite loss), which are differently 
affected by the various antidepressants, or utilise the anxio-
lytic effects of some antidepressants to treat both depression 
and co-existing anxiety [46].
While clinicians may prefer to defer pharmacotherapy 
for those patients with symptoms of depression or anxiety 
whose screening scores are below the cut-points for diagno-
sis as probable cases, such patients should be monitored for 
later deterioration. It is important to note that the adverse 
effects of depression and anxiety each played out across 
the spectrum of severity; so restricting treatment or addi-
tional support only to those patients who are categorised 
as probable cases disregards the negative impact of milder 
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depression or anxiety. Non-pharmacotherapeutic treatments 
such as acceptance and commitment therapy [47] or mind-
fulness [48] may be useful options. Depression emerges as 
an important factor meriting particular clinical vigilance and 
willingness to intervene, because it has a strong association 
with both physical and psychological QoL.
In conclusion, quality of life for people living with ALS/
MND is a dynamic, multidimensional construct and this 
should be accounted for during research and care. System-
atic and repeated assessments of pain, depression and anxi-
ety emerge as worthwhile additions to comprehensive care, 
because these are common and treatable symptoms which 
impact upon the QoL of those living with ALS/MND.
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